問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Rheumatology

Division of Radiology

Division of General Internal Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

China Medical University Hospital
Taipei Veterans General Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

李劭軒Li, Shau-Hsuan
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • lee056058@gmail.com

  • nana.fen.tw@gmail.com

Recruiting Trial

151Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李劭軒

List

274Cases

2024-01-15 - 2029-12-31

Phase III

Active
Beamion LUNG-2: A Phase III, open-label, randomized, active- controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Condition/Disease

    unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Test Drug

    Zongertinib

Participate Sites
5Sites

Recruiting5Sites

2015-09-15 - 2019-09-30

Phase III

Completed
A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs

  • Condition/Disease

    Esophageal cancer

  • Test Drug

    ONO-4538 (Nivolumab)

Participate Sites
13Sites

Terminated11Sites

林振源
China Medical University Hospital-Taipei

未分科

顏厥全
Taipei Veterans General Hospital

Division of Hematology & Oncology

2020-01-01 - 2026-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer

  • Condition/Disease

    RESECTION NSCLC

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mLOPDIVO (nivolumab) Injection 10mg/mL

Participate Sites
4Sites

Recruiting4Sites

2024-10-01 - 2034-06-01

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Recruiting5Sites

2020-04-01 - 2025-11-26

Phase III

Completed
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

  • Condition/Disease

    Previously Untreated, Locally Advanced Non-small Cell Lung Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL OPDIVO (nivolumab) Injection 10mg/mL YERVOY (ipilimumab) Injection 5mg/mL YERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2018-08-01 - 2026-12-01

Phase III

Active
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ≥ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    NON-SMALL CELL LUNG CANCER (NSCLC)

  • Test Drug

    RO5424802(Alctinib)、capsule、 150mg

Participate Sites
9Sites

Recruiting8Sites

2023-04-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2016-09-19 - 2019-08-23

Phase II/III

Completed
Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)

  • Condition/Disease

    methothlioma

  • Test Drug

    ADI-PEG 20

Participate Sites
7Sites

Terminated6Sites

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

2019-01-01 - 2025-12-31

Phase I

Completed
Phase 1-2 Study of ADI PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular carcinoma

  • Test Drug

    ADI-PEG20

Participate Sites
13Sites

Terminated12Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2022-06-01 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 16 17 18 19 20 28
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB